Novel injectable biosensor for continuous remote monitoring of cancer patients at high-risk of relapse

SENTINEL aims at developing a minimally invasive and biocompatible implantable biosensor to be used in the early tumor surveillance in post-operative prostate cancer patients. Placed under the user’s skin, the sensor allows optical readout of the patient’s disease state using a portable probe, which acquired signals are then analysed using machine learning algorithms to infer the disease status.

How it will work

The technology will

  Ø increase the positive predictive value of cancer screening

 Ø facilitate the remote and ubiquitous monitoring of patients in large scale

This technology is intended to support simple, affordable implantation procedures by a physician and allow surveillance of early-stage cancer recurrence in high-risk profile patients as to enhance positive predictive value (PPV) of cancer screening and reduction of false positives

SENTINEL opens a new avenue for nanotechnology integration of monitoring devices in healthcare, which can significantly contribute to improve early disease diagnosis and treatment of patients.

The technology proposed can be applied to other healthcare segments, with special emphasis to monitoring of chronic and metabolic diseases - monitoring of many other biomolecular species is deemed possible

This project is supported under the framework of the Incentive Scheme to Research And Technological Development (Si I&Dt), Corporate R&D – Copromotion Projects: International Partnerships